Vor Biopharma Inc. Stock Price, News & Analysis

Vor Bio (Nasdaq: VOR), a leader in cell and genome engineering, is set to participate in several important investor conferences. The events include:

• Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on April 24, 2023, at 9:30 am ET.
• H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 12:00 pm ET, located at Nasdaq World Headquarters, New York, NY.
• The JMP Securities Life Sciences Conference on May 16, 2023, at 3:00 pm ET, taking place at New York Hilton Midtown.

Live webcasts and archived replays of these sessions will be accessible on their investor relations website.

Vor Bio focuses on enhancing treatment options for blood cancer patients through innovative stem cell engineering.

Vor Bio (Nasdaq: VOR) has announced initial clinical data from its VBP101 study, indicating potential treatment advancements post-acute myeloid leukemia (AML) transplant. The company plans to submit an Investigational New Drug (IND) application for VCAR33^ALLO in early 2023 and expects additional trem-cel data by the end of the year. A recent financing round raised $116 million, extending cash reserves until Q1 2025. Despite increased R&D and administrative expenses, Vor Bio reported a net loss of $92.1 million for 2022, up from $68.9 million in 2021. The company aims to revolutionize care for blood cancers with genome-edited stem cell therapies.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in several upcoming investor conferences. Notable events include the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, and the Mizuho Oncology Therapeutics Summit on March 13, 2023, in Miami, FL. Vor Bio will also present at the Oppenheimer 33rd Annual Virtual Healthcare Conference on the same day and will attend the Barclays Global Healthcare Conference on March 15, 2023. Investors can access a live webcast and archived replays of these presentations through their website.

Vor Bio (Nasdaq: VOR) has presented promising clinical data from its VBP101 study on trem-cel, a genome-edited therapy targeting acute myeloid leukemia (AML). The therapy demonstrated robust engraftment in the first patient five months post-transplant, maintaining hematopoiesis through three cycles of Mylotarg, with no significant adverse effects. The second patient also achieved successful neutrophil engraftment and platelet recovery. Data showed Mylotarg's potential to protect against hematological toxicity and enrich CD33-negative donor cells. Vor Bio plans to escalate Mylotarg doses and submit an IND for VCAR33^ALLO, a new CAR-T therapy, in H1 2023.

Vor Bio (Nasdaq: VOR) announced that clinical data from the initial patient treated in its VBP101 study has been accepted for presentation at the 2023 Tandem Meetings from February 15-19 in Orlando, Florida. This Phase 1/2a trial is focused on trem-cel (formerly VOR33) for patients with acute myeloid leukemia (AML). The late-breaking poster presentation, titled "Initial First-in-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT)," will showcase important findings including tolerability of Gemtuzumab Ozogamicin without cytopenias.